Posts by: Joana Carvalho, PhD

Joana Carvalho, PhD

Joana holds a BSc in Biology, a MSc in Evolutionary and Developmental Biology and a PhD in Biomedical Sciences from Universidade de Lisboa, Portugal. Her work has been focused on the impact of non-canonical Wnt signaling in the collective behavior of endothelial cells — cells that made up the lining of blood vessels — found in the umbilical cord of newborns.

December 20, 2019December 20, 2019

LHON Natural History Study Highlights Improvements in Visual Acuity From Lumevoq Treatment

News

Patients with Leber hereditary optic neuropathy (LHON), a rare genetic mitochondrial disease that causes vision loss, experienced a dramatic and mostly irreversible loss of visual acuity, according to an ... Read more

December 6, 2019December 17, 2019

New Mouse Model May Advance Understanding of Mitochondria Protein Production and Dysfunction, Researchers Say

News

A new mouse model may help scientists deepen their knowledge about mitochondria, the cell compartments responsible for the production of energy in the body, as well as their understanding ... Read more

October 4, 2019October 4, 2019

Mutation in Nuclear Gene Associated with Symptoms of Mitochondrial Disease, Case Report Shows

News

A recent report that describes the case of a teenager with severe symptoms of multiple mitochondrial diseases, contends it may have been caused by a mutation in a gene ... Read more

September 27, 2019September 27, 2019

GS010 Gene Therapy Continues to Improve Visual Acuity in LHON Patients After Two Years, Trial Data Show

News

GS010, a gene therapy developed by GenSight Biologics, continues to lead to sustained improvements in visual acuity in patients with Leber hereditary optic neuropathy (LHON), a rare genetic mitochondrial ... Read more

July 19, 2019July 19, 2019

GenSight Completes Enrollment Early for Phase 3 Trial of GS010 Gene Therapy

News

GenSight Biologics has completed full patient enrollment ahead of schedule for its ongoing Phase 3 trial assessing the safety and efficacy of GS010, the company’s gene therapy designed to ... Read more

June 14, 2019June 14, 2019

Symptoms Vary Greatly in People with MT-ATP6 Mutations and Better Tests Needed, Study Says

News

Symptoms vary greatly among people with mitochondrial disease linked to any one of the many mutations evident in the MT-ATP6 gene, a study found, and its researchers call for better tests ... Read more

May 31, 2019May 31, 2019

Reneo Pharmaceuticals Raises $50M to Support Development of Therapies for Mitochondrial Diseases

News

Reneo Pharmaceuticals has raised $50 million to support the development of therapies for mitochondrial diseases associated with defects in cells’ metabolism and energy production. The company’s fundraising includes contributions ... Read more

February 8, 2019February 8, 2019

Topline Results Announced for Phase 3 Trial Testing GS010 in LHON Patients

News

GenSight Biologics annnounced the topline results of a Phase 3 clinical trial for GS010, a gene therapy designed to improve vision acuity in patients with Leber hereditary optic neuropathy (LHON), ... Read more

January 4, 2019January 4, 2019

AOX Enzyme May Alleviate Symptoms of Mitochondrial Disease, Mouse Study Shows

News

Researchers found an enzyme called alternative oxidase (AOX) that is able to bypass part of the mitochondrial respiratory chain (MRC) and alleviate symptoms of mitochondrial cardiomyopathy in a mouse ... Read more

December 14, 2018December 14, 2018

GS010 Improves Visual Acuity, Quality of Life in LHON Patients, Phase 3 Trial Shows

News

GS010, a gene therapy developed by GenSight Biologics, improves visual acuity and quality of life in patients with Leber hereditary optic neuropathy (LHON), a rare genetic mitochondrial disease that causes ... Read more